SCHEMBL22005107

SCHEMBL22005107

COC(=O)c1cc2c(cc1Cl)cc(-c1cncnc1)n2C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 4/20 0.59
NR4A2 P43354 3/20 0.39
MAOA P21397 1/20 0.39
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
CYP11B2 P19099 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
MAPT P10636 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
TTK P33981 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22005118 0.86 ACLY (0.55) ACLYMAOACYP11B2KMT2A
SCHEMBL22005109 0.85 ACLY (0.56) ACLYNR4A2MAOAHTR2AHTR2C
SCHEMBL22004321 0.76 HPGD (0.41) ACLYL3MBTL1MAPTNPSR1KMT2A
SCHEMBL22004214 0.75 ACLY (1.00) ACLY
SCHEMBL22005117 0.71 ACLY (0.53) ACLYMAOAMAPTKMT2AKDM4E
SCHEMBL17185620 0.71 PDK2 (0.48) ACLYNR4A2CYP11B2L3MBTL1MAPT
SCHEMBL22004125 0.69 ACLY (0.49) ACLYMAOACYP11B2MAPTKMT2A
SCHEMBL23591216 0.68 ALDH1A1 (0.43) MAPTNPSR1KMT2AKDM4EALDH1A1
SCHEMBL30183843 0.68 ALDH1A1 (0.43) MAPTNPSR1KMT2AKDM4EALDH1A1
SCHEMBL8706096 0.68 ACLY (0.46) ACLYNR4A2MAPTNPSR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200157076-A1 ACLY INHIBITORS AND USES THEREOF NIMBUS DISCOVERY, INC. 2020-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200157076-A1 ACLY INHIBITORS AND USES THEREOF ACLY, ATP5ME, ATP5MG ACLY 1/4885NR4A2 4503/4885MAOA 3294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.